{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:53:11Z","timestamp":1768283591226,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Aliskiren, a renin inhibitor, has been shown to have cardioprotective and blood pressure (BP) lowering effects. We aimed to determine the effects of nanoparticle-loaded aliskiren on BP, nitric oxide synthase activity (NOS) and structural alterations of the heart and aorta developed due to spontaneous hypertension in rats. Twelve week-old male spontaneously hypertensive rats (SHR) were divided into the untreated group, group treated with powdered or nanoparticle-loaded aliskiren (25 mg\/kg\/day) and group treated with nanoparticles only for 3 weeks by gavage. BP was measured by tail-cuff plethysmography. NOS activity, eNOS and nNOS protein expressions, and collagen content were determined in both the heart and aorta. Vasoactivity of the mesenteric artery and wall thickness, inner diameter, and cross-sectional area (CSA) of the aorta were analyzed. After 3 weeks, BP was lower in both powdered and nanoparticle-loaded aliskiren groups with a more pronounced effect in the latter case. Only nanoparticle-loaded aliskiren increased the expression of nNOS along with increased NOS activity in the heart (by 30%). Moreover, nanoparticle-loaded aliskiren decreased vasoconstriction of the mesenteric artery and collagen content (by 11%), and CSA (by 25%) in the aorta compared to the powdered aliskiren group. In conclusion, nanoparticle-loaded aliskiren represents a promising drug with antihypertensive and cardioprotective effects.<\/jats:p>","DOI":"10.3390\/molecules24152710","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T08:45:39Z","timestamp":1564130739000},"page":"2710","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats"],"prefix":"10.3390","volume":"24","author":[{"given":"Olga","family":"Pechanova","sequence":"first","affiliation":[{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Barta","sequence":"additional","affiliation":[{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Koneracka","sequence":"additional","affiliation":[{"name":"Institute of Experimental Physics, Slovak Academy of Sciences, Watsonova 47, 040 01 Kosice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlasta","family":"Zavisova","sequence":"additional","affiliation":[{"name":"Institute of Experimental Physics, Slovak Academy of Sciences, Watsonova 47, 040 01 Kosice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kubovcikova","sequence":"additional","affiliation":[{"name":"Institute of Experimental Physics, Slovak Academy of Sciences, Watsonova 47, 040 01 Kosice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Klimentova","sequence":"additional","affiliation":[{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"T\u04e7r\u04e7k","sequence":"additional","affiliation":[{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zemancikova","sequence":"additional","affiliation":[{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0132-670X","authenticated-orcid":false,"given":"Martina","family":"Cebova","sequence":"additional","affiliation":[{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11906-019-0949-4","article-title":"New Approaches in Hypertension Management: A Review of Current and Developing Technologies and Their Potential Impact on Hypertension Care","volume":"21","author":"Kitt","year":"2019","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_2","unstructured":"Iqbal, A.M., and Jamal, S.F. (2019, April 03). Essential Hypertension, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539859\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/HYP.0000000000000003","article-title":"An effective approach to high blood pressure control: A science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention","volume":"63","author":"Go","year":"2014","journal-title":"Hypertension"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.amepre.2017.06.020","article-title":"Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review","volume":"53","author":"Park","year":"2017","journal-title":"Am. J. Prev. Med."},{"key":"ref_5","first-page":"008276","article-title":"Pharmacotherapy for hypertension in adults aged 18 to 59 years","volume":"2017","author":"Gueyffier","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrcardio.2010.85","article-title":"Novel therapeutic targets for hypertension","volume":"7","author":"Paulis","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pantzaris, N.-D., Karanikolas, E., Tsiotsios, K., and Velissaris, D. (2017). Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J. Clin. Med., 6.","DOI":"10.3390\/jcm6060061"},{"key":"ref_8","first-page":"CD007066","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension","volume":"2017","author":"Lawrence","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem. Boil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.12659\/MSM.883949","article-title":"Direct renin inhibition\u2014A promising strategy for renal protection?","volume":"19","author":"Lizakowski","year":"2013","journal-title":"Med. Sci. Monit."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/VHRM.S4291","article-title":"Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors","volume":"5","author":"Oparil","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-0043-119068","article-title":"Renin inhibition by aliskiren protects rats against isoproterenol induced myocardial infarction","volume":"68","author":"Khan","year":"2018","journal-title":"Drug Res."},{"key":"ref_13","first-page":"623","article-title":"Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor","volume":"60","author":"Buczko","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200847080-00002","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren","volume":"47","author":"Vaidyanathan","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ejhf.896","article-title":"Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: A subgroup analysis from the ATMOSPHERE trial","volume":"20","author":"Kristensen","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chou, C.-L., Lin, H., Chen, J.-S., and Fang, T.-C. (2017). Renin inhibition improves metabolic syndrome, and reduces angiotensin II levels and oxidative stress in visceral fat tissues in fructose-fed rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180712"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2018.08.053","article-title":"Moderate-intensity exercise and renin angiotensin system blockade improve the renovascular hypertension (2K1C)-induced gastric dysmotility in rats","volume":"210","author":"Telles","year":"2018","journal-title":"Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","article-title":"PLGA Nanoparticles in Drug Delivery: The State of the Art","volume":"21","author":"Bala","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/21691401.2016.1146731","article-title":"Biodegradable and biocompatible polymers for tissue engineering application: A review","volume":"45","author":"Asghari","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10717544.2016.1255999","article-title":"Nanocarriers as treatment modalities for hypertension","volume":"24","author":"Alam","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: An overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-5173(02)00076-5","article-title":"Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration","volume":"239","author":"Ahlin","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jmmm.2014.10.089","article-title":"Magnetic poly(d,l-lactide) nanoparticles loaded with aliskiren: A promising tool for hypertension treatment","volume":"380","author":"Antal","year":"2015","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.eurpolymj.2004.09.015","article-title":"Characterization and release of triptolide-loaded poly (d,l-lactic acid) nanoparticles","volume":"41","author":"Liu","year":"2005","journal-title":"Eur. Polym. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jmmm.2006.11.177","article-title":"Encapsulation of indomethacin in magnetic biodegradable polymer nanoparticles","volume":"311","author":"Zavisova","year":"2007","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11906-009-0077-7","article-title":"Direct renin inhibition: An update","volume":"11","author":"Pinto","year":"2009","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"89364","DOI":"10.18632\/oncotarget.19382","article-title":"Aliskiren therapy in hypertension and cardiovascular disease: A systematic review and a meta-analysis","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e000606","DOI":"10.1161\/JAHA.113.000606","article-title":"Direct Renin Inhibition With Aliskiren Protects Against Myocardial Ischemia\/Reperfusion Injury by Activating Nitric Oxide Synthase Signaling in Spontaneously Hypertensive Rats","volume":"3","author":"Zhang","year":"2014","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_29","first-page":"957","article-title":"Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats","volume":"78","author":"Pfeffer","year":"1971","journal-title":"J. Lab. Clin. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.bjp.0700910","article-title":"The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats","volume":"120","author":"Kim","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.msec.2013.10.038","article-title":"Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design","volume":"35","author":"Shah","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"H278","DOI":"10.1152\/ajpheart.00471.2017","article-title":"VEGF nanoparticles repair the heart after myocardial infarction","volume":"314","author":"Oduk","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2174\/1389450117666160711163119","article-title":"Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics","volume":"18","author":"Niaz","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.biotechadv.2015.01.005","article-title":"State of the art, challenges and perspectives in the design of nitric oxide-releasing polymeric nanomaterials for biomedical applications","volume":"33","author":"Seabra","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/1440-1681.12550","article-title":"Aliskiren improves endothelium-dependent relaxation of thoracic aorta by activating PI3K\/Akt\/eNOS signal pathway in SHR","volume":"43","author":"Gu","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/jat.3470","article-title":"The use of human umbilical vein endothelial cells (HUVECs) as an in vitro model to assess the toxicity of nanoparticles to endothelium: A review","volume":"37","author":"Cao","year":"2017","journal-title":"J. Appl. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/bab.46","article-title":"Biocompatibility of amorphous silica nanoparticles: Size and charge effect on vascular function, in vitro","volume":"58","author":"Akbar","year":"2011","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/1470320314528364","article-title":"Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration","volume":"16","author":"Ferri","year":"2015","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_39","first-page":"684","article-title":"Aliskiren inhibits proliferation of cardiac fibroblasts in AGT-REN double transgenic hypertensive mice in vitro","volume":"68","author":"Wang","year":"2016","journal-title":"Acta Physiol. Sin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0168-3659(02)00210-9","article-title":"Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods","volume":"83","author":"Chorny","year":"2002","journal-title":"J. Control. Rel."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/CS20050227","article-title":"Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension","volume":"110","author":"Zicha","year":"2006","journal-title":"Clin. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/15\/2710\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:09:36Z","timestamp":1760188176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/15\/2710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":41,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["molecules24152710"],"URL":"https:\/\/doi.org\/10.3390\/molecules24152710","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]}}}